Prospective Observational Study of a Precision Medicine Approach in Patients With Advanced Cancer

Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · Jun 21, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new approach called precision medicine for patients with advanced cancer. Precision medicine focuses on understanding the unique characteristics of a person's cancer by looking at their genetic makeup. In this study, patients will undergo detailed testing to identify specific changes in their cancer cells, which will help doctors tailor treatments that are more likely to work for them. Researchers at Charité University Medicine in Berlin will monitor these patients to see how effective this personalized approach is and to learn more about the different types of molecular changes they find.

To participate in the trial, patients need to have advanced cancer and must be able to provide written consent. They also should be in good enough health to start a new treatment after their tests. Importantly, patients will receive support throughout the process and may have access to new therapies based on their individual cancer profiles. This study is currently recruiting participants, and it welcomes patients of all ages and genders who meet the criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • advanced cancer
• • ability to give written informed consent
• • performance status allows initiation of a potential targeted treatment after molecular analysis
• • molecular analysis has been done or planned
• Exclusion Criteria:
• • - unable to give written informed consent